Gojihvadi Kwath: The Childhood Rhinitis Trial, in Detail

TL;DR

In a December 2022 randomized, open-label trial (Indian Journal of Applied Research), 40 children aged 2–12 with pratishyaya (allergic rhinitis) received Gojihwadi syrup or Vyoshadi syrup for 14 days. In the Gojihwadi arm (n=20): 8 marked improvement, 11 moderate, 1 complete relief. The comparator performed better overall. No adverse reactions were observed during the study. (57 words)

What it is

Gojihvadi Kwath is a kwatha, a classical decoction formulation, that the trial paper describes as "a collection of Ayurvedic and Unani drugs described in Siddha Yoga Sangraha under Jwara rog adhikara," the fever section of Yadavji Trikamji's compendium (trial paper/recent_issues_pdf/2022/December/a-comparative-clinical-study-of-vyoshadi-churna-and-gojihwadi-kwath-in-pratishyaya-allergic-rhinitis_December_2022_9567143706_2011583.pdf)). The paper spells it "Gojihwadi"; both transliterations refer to the same formulation.

The trial's composition lists 16 ingredients by their Sanskrit names: Gojihwa, Draksha, Yashtimadhu, Vasa, Hansraj, Khatmi, Gulbanaffsa, Mishreya, Anjeer, Unnav, Jufa, Sapistan, Khubkalan, Alasi, Maricha, and Kantakari. That list comes from the published paper itself, not a vendor page, which makes it the most reliable composition on record. For the trial, the kwatha was prepared per the Sharangdhara Samhita method (200 g of each drug in coarse powder, boiled in 16 parts water and reduced to one-eighth), converted to a syrup with sugar for palatability in children, preserved with 0.3% sodium benzoate, and manufactured by a GMP-certified Ayurveda pharmacy in Haridwar.

Traditional use

The classical anchoring is narrow and specific: Siddha Yoga Sangraha places this formulation under its jwara (fever) section, and the trial investigators selected it for pratishyaya, the Ayurvedic correlate of allergic rhinitis. Broader indication lists found on commercial pages (cough, bronchitis, asthma, dosha-balancing claims) could not be traced to a primary source and are not repeated here.

What modern research says

The evidence is one small, open-label, single-center trial, worth describing precisely because its limits matter as much as its numbers.

The study. Panchola, Singh, and Garg (Department of Kaumarbhritya, Uttarakhand Ayurved University, Haridwar) ran a randomized, open-label, parallel-arm trial in 40 children aged 2–12 with classical pratishyaya symptoms, registered with the Clinical Trials Registry of India (CTRI/2020/05/025105) and cleared by the institutional ethics committee. Children with tuberculosis, diabetes, pneumonia, asthma, deviated nasal septum, nasal polyps, or nasal tumors were excluded. Randomization was by lottery: 20 children received Vyoshadi syrup (Group A), 20 received Gojihwadi syrup (Group B), for 14 days, with assessments at days 7, 14, and 21. The comparator, Vyoshadi churna, is itself a classical formulation, mentioned by Chakrapani in the Chikitsa Sangraha under nasal disorders, so this was a head-to-head of two traditional preparations, not a placebo trial.

The results. Primary endpoints were the classical signs and symptoms of pratishyaya (headache, rhinorrhea, nasal itching, cough, anosmia, sneezing, nasal congestion); secondary endpoints were blood indices (TLC, DLC, ESR, AEC). Outcomes in the Gojihwadi arm (n=20): marked improvement in 8 children (40%), moderate improvement in 11 (55%), complete relief in 1 (5%). In the Vyoshadi arm: marked improvement in 12 (60%), moderate in 5 (25%), complete relief in 3 (15%). The authors concluded both syrups had a significant effect on pratishyaya symptoms, with Vyoshadi showing the better result overall.

The caveats. Open-label means no blinding: expectations could have influenced symptom reporting. Forty children at one center, over 14 days with one week of follow-up, is a small, short window. And the honest headline: the formulation underperformed its comparator. This is preliminary evidence of symptomatic improvement in a small pediatric sample, not proof of efficacy.

Dosage

The trial's regimen (not a general recommendation) was dosed by age: 1 teaspoon twice daily for ages 2–5, 1.5 teaspoons twice daily for ages 6–9, and 2 teaspoons twice daily for ages 10–12, for 14 days (trial paper/recent_issues_pdf/2022/December/a-comparative-clinical-study-of-vyoshadi-churna-and-gojihwadi-kwath-in-pratishyaya-allergic-rhinitis_December_2022_9567143706_2011583.pdf)). No pharmacopoeial dose for Gojihvadi Kwath was located, so no general dosage is given here.

Safety & contraindications

"No ADR was observed in any of the participants during this study": that is the paper's safety finding, in full. Forty children, fourteen days, one preparation, one pharmacy's batch. It does not establish safety in general, in adults, in pregnancy, or over longer use. Allergic rhinitis in children deserves a pediatrician's or qualified vaidya's assessment, not a syrup ordered on the strength of one small trial.

FAQs

What is Gojihvadi Kwath?

A classical Ayurvedic decoction (kwatha) formulation of 16 herbs, described in Siddha Yoga Sangraha under its fever section. In the published trial it was prepared as a sweetened syrup to make it palatable for children. (The paper spells it "Gojihwadi.")

What is Gojihvadi Kwath made of?

The trial paper lists 16 ingredients: Gojihwa, Draksha, Yashtimadhu, Vasa, Hansraj, Khatmi, Gulbanaffsa, Mishreya, Anjeer, Unnav, Jufa, Sapistan, Khubkalan, Alasi, Maricha, and Kantakari, prepared as a decoction per the Sharangdhara Samhita method.

Does Gojihvadi Kwath work for allergic rhinitis?

One small trial suggests symptomatic improvement: among 20 children, 8 had marked improvement, 11 moderate, and 1 complete relief over 14 days. But the trial was open-label, single-center, and short, and the comparator syrup did better. Consider it preliminary, not proven.

Which worked better: Gojihvadi or Vyoshadi?

Vyoshadi syrup, in this trial: 60% marked improvement and 15% complete relief, versus 40% and 5% for Gojihwadi. The authors' own conclusion favors Vyoshadi.

How was it dosed in the trial?

By age, twice daily for 14 days: 1 teaspoon (ages 2–5), 1.5 teaspoons (6–9), 2 teaspoons (10–12). This was the trial protocol, not a general dosing recommendation.

Is Gojihvadi Kwath safe for children?

The trial reported no adverse drug reactions in its 40 participants over the study period. That is reassuring but narrow. It does not cover other ages, longer use, or other manufacturers' batches. Get a clinician's guidance first.

Sources

Disclaimer

This article is for education only, not medical advice. Ayurvedic herbs can interact with medicines and are unsafe in some conditions. Talk to a qualified practitioner before using any herb or formulation.